Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 52, 6164-6167, November 15, 1992]
© 1992 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Butler, W. B.
Right arrow Articles by Fontana, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Butler, W. B.
Right arrow Articles by Fontana, J. A.

Resonses to Retinoic Acid of Tamoxifen-sensitive and -resistant Sublines of Human Breast Cancer Cell Line MCF-71

W. Barkely Butler2 and Joseph A. Fontana

Department of Biology, Indiana University of Pennsylvania, Indiana, Pennsylvania 15705 [W. B. B.], and Department of Medicine, University of Maryland Cancer Center, Baltimore, Maryland 21201 [J. A. F.]

Growth of the human breast cancer cell line MCF-7 is known to be inhibited both by antiestrogens such as 4-hydroxytamoxifen (OHTAM) and by retinoic acid (RA). Uncloned MCF-7 cells (UNC) and two cloned sublines, one sensitive to antiestrogens (E-3) and the other resistant to them (RR), were used in this study. Growth of UNC and E-3 was inhibited by either OHTAM (10-7 M) or RA (10-6 M), and this inhibition could not be overcome by the simultaneous addition of estradiol. Subline RR, which was originally selected for resistance to tamoxifen, was resistant to both OHTAM and RA as measured by either growth in culture or colony forming ability. RR was resistant to RA at all concentrations tested between 10-9 M and 10-6 M. The inhibition of uncloned MCF-7 cells by RA was dose dependent between 10-9 M and 10-6 M. Subline E-3, however, exhibited a mixed response to RA. At 10-9 M and 10-8 M, growth was stimulated, but at 10-7 M and 10-6 M it was inhibited. The level of estrogen receptor was measured in the same experiment by using a whole cell assay. In the uncloned MCF-7 cultures and in both the RR and E-3 sublines the level of estrogen receptor was increased between 50 and 200% by RA.

The production of plasminogen activator by MCF-7 cells is stimulated by estrogen. RA had a dual effect on plasminogen activator production. In the absence of estrogen, RA inhibited production below the unstimulated level, but in cells stimulated by estrogen, RA increased plasminogen activator production. The results reported here support possible interactions between the mechanisms by which cells respond to estrogen, antiestrogens, and retinoids.

1 Supported by USPHS Grants CA-21606 and CA-43868; by Senate Fellowship Grants from Indiana University of Pennsylvania; and Grants from the Faculty Professional Development Council of the State System of Higher Education, Commonwealth of Pennsylvania.

2 To whom requests for reprints should be addressed, at Department of Biology, Indiana University of Pennsylvania, Indiana, PA 15705.

Received 1/17/90. Accepted 9/ 9/92.




This article has been cited by other articles:


Home page
J EndocrinolHome page
D N Danforth Jr
All trans-retinoic acid acts synergistically with hydroxytamoxifen and transforming-growth factor {beta} to stimulate apoptosis in MCF-7 breast cancer cells
J. Endocrinol., November 1, 2004; 183(2): 395 - 404.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. A. Lawrence, P. C. Adamson, R. Caruso, C. Chow, D. Kleiner, R. F. Murphy, D. J. Venzon, M. Shovlin, M. Noone, M. Merino, et al.
Phase I Clinical Trial of Alitretinoin and Tamoxifen in Breast Cancer Patients: Toxicity, Pharmacokinetic, and Biomarker Evaluations
J. Clin. Oncol., May 15, 2001; 19(10): 2754 - 2763.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar
Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance
Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1992 by the American Association for Cancer Research.